Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease
| Autor: | Qi-Lin Ma, He-Li, Yin-Xiao Du, Kong-Xiang Zhu, Xiao-Ping Chen, Pei-Yuan Song, Li-Ming Peng, Mu-Peng Li |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Genotype medicine.medical_treatment Coronary Artery Disease CYP2C19 030226 pharmacology & pharmacy Gastroenterology Loading dose Coronary artery disease 03 medical and health sciences 0302 clinical medicine Asian People Internal medicine medicine Humans Pharmacology (medical) cardiovascular diseases 030212 general & internal medicine Aged Pharmacology Aspirin Polymorphism Genetic Maintenance dose business.industry Dual Anti-Platelet Therapy Percutaneous coronary intervention General Medicine Middle Aged medicine.disease Clopidogrel Thrombosis Cytochrome P-450 CYP2C19 Oxygenases Female business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | European Journal of Clinical Pharmacology. 77:359-368 |
| ISSN: | 1432-1041 0031-6970 |
| Popis: | Dual antiplatelet therapy with aspirin and clopidogrel is commonly used for coronary artery disease (CAD) patients undergoing percutaneous coronary intervention to prevent stent thrombosis and ischemic events. However, some patients show high on-treatment platelet reactivity (HTPR) during clopidogrel therapy. Genetic factors such as loss-of-function variants of CYP2C19 are validated to increase the risk of HTPR. Flavin-containing monooxygenase 3 (FMO3) is reported to be associated with potency of platelet responsiveness and thrombosis. This study aimed to explore the association between FMO3 rs1736557 polymorphism and clopidogrel response. Five hundred twenty-two Chinese CAD patients treated with dual antiplatelet therapy were recruited from Xiangya Hospital. After oral administration of 300 mg loading dose (LD) clopidogrel for 12–24 h or 75 mg daily maintenance dose (MD) clopidogrel for at least 5 days, the platelet reaction index (PRI) was determined by vasodilator-stimulated phosphoprotein-phosphorylation assay. FMO3 rs1736557, CYP2C19*2, and CYP2C19*3 polymorphisms were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Mean PRI value was significantly higher in CYP2C19 poor metabolizers (PMs) and intermediate metabolizers (IMs) than the extensive metabolizers (EMs) (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink